Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M205326200 on June 26, 2002

J. Biol. Chem., Vol. 277, Issue 36, 32883-32891, September 6, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/36/32883    most recent
M205326200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bertrand, G.
Right arrow Articles by Henquin, J.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bertrand, G.
Right arrow Articles by Henquin, J.-C.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The Elevation of Glutamate Content and the Amplification of Insulin Secretion in Glucose-stimulated Pancreatic Islets Are Not Causally Related*

Gyslaine BertrandDagger §, Nobuyoshi IshiyamaDagger , Myriam NenquinDagger , Magalie A. RavierDagger , and Jean-Claude HenquinDagger

From the Dagger  Unité d'Endocrinologie et Métabolisme, University of Louvain Faculty of Medicine, B-1200 Brussels, Belgium and the § Unité Propre de Recherche 9023, Centre National de la Recherche Scientifique, F-34094 Montpellier, France

Received for publication, May 30, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Glucose increases insulin secretion by raising cytoplasmic Ca2+ ([Ca2+]i) in beta -cells (triggering pathway) and augmenting the efficacy of Ca2+ on exocytosis (amplifying pathway). It has been suggested that glutamate formed from alpha -ketoglutarate is a messenger of the amplifying pathway (Maechler, P., and Wollheim, C. B. (1999) Nature 402, 685-689). This hypothesis was tested with mouse islets depolarized with 30 mM KCl (+ diazoxide) or with a saturating concentration of sulfonylurea. Because [Ca2+]i was elevated under these conditions, insulin secretion was stimulated already in 0 mM glucose. The amplification of secretion produced by glucose was accompanied by an increase in islet glutamate. However, glutamine (0.5-2 mM) markedly augmented islet glutamate without affecting insulin secretion, whereas glucose augmented secretion without influencing glutamate levels when these were elevated by glutamine. Allosteric activation of glutamate dehydrogenase by BCH (2-amino 2-norbornane carboxylic acid) lowered islet glutamate but increased insulin secretion. Similar insulin secretion thus occurred at very different cellular glutamate levels. Glutamine did not affect islet [Ca2+]i and pHi, whereas glucose and BCH slightly raised pHi and either slightly decreased (30 mM KCl) or increased (tolbutamide) [Ca2+]i. The general dissociation between changes in islet glutamate and insulin secretion refutes a role of beta -cell glutamate in the amplification of insulin secretion by glucose.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Tight control of insulin secretion by pancreatic beta -cells is critical for glucose homeostasis. This control is exerted by a number of physiological agents, among which circulating nutrients, in particular glucose, play a central role. Glucose regulation of insulin secretion involves two major signaling pathways leading to the production of triggering and amplifying signals respectively (1). The triggering pathway consists in a now well accepted cascade of events. The metabolism of glucose by oxidative glycolysis causes a rise in the ATP/ADP ratio, which closes ATP-sensitive K+ (K+-ATP)1 channels. The resulting decrease in K+ conductance leads to membrane depolarization, with subsequent opening of voltage-dependent Ca2+ channels, Ca2+ influx from the extracellular space, and rise in the concentration of free cytoplasmic Ca2+ ([Ca2+]i), which triggers the exocytosis of insulin granules (2-7). However, the triggering action of Ca2+ does not completely explain the stimulation of insulin secretion by glucose. Amplifying signals are also produced in beta -cells, and these augment the magnitude of the secretory response, in particular during the sustained phase of stimulation (8-10). Whereas the importance of this pathway is now undisputed (1), the underlying mechanisms remain controversial (1, 11-16).

The present study was prompted by the current controversy surrounding the hypothesis that intracellular glutamate, formed through amination of alpha -ketoglutarate by glutamate dehydrogenase (GDH), may serve as second messenger in this amplifying pathway (17). The hypothesis was originally based on the observations that glutamate increased insulin release from permeabilized INS-1 cells perifused with elevated fixed concentrations of Ca2+ and ATP, that glucose increased insulinoma and islet cell glutamate content, and that a membrane-permeant ester of glutamate increased insulin secretion from intact cells (17). On the other hand, the hypothesis was contradicted by reports suggesting that glucose does not affect glutamate levels in islets from ob/ob mice (18, 19) or rats (20) and in insulinoma cells (15). In addition, the ability of glutamate dimethyl ester to increase insulin secretion has been attributed to its use as a nutrient by beta -cells (21).

Manipulations of the genes coding for glutamate decarboxylase (GAD) and for GDH have also yielded conflicting results. Overexpression of GAD65 in INS-1E cells increased the enzyme activity 26-fold, lowered cell glutamate content by ~40%, but inhibited insulin secretion (40%) at 15 mM glucose only, being without effect at 2.5 and 7.5 mM glucose (22). Overexpression of GAD65 in rat islet cells did not affect insulin secretion in response to 8.3 mM glucose but inhibited the sustained response to 16.7 mM glucose (22). These results were considered to support the role of glutamate in glucose-induced insulin secretion. In contrast, transgenic mice overexpressing GAD65 in beta -cells, normally released insulin in response to high glucose; the only defect was an inhibition of first phase insulin release induced by 7 mM glucose. The study was considered not to support the glutamate hypothesis (23). Overexpression of GDH in INS-1E cells increased human growth hormone release (reporter of insulin release by transfected cells) induced by high glucose without affecting basal release. It was assumed, not verified, that the overexpressed enzyme was working in the direction of alpha -ketoglutarate to glutamate and thus increasing the concentration of glutamate (24). Conversely, overexpression of a mutated, constitutively active GDH in MIN6 cells increased insulin release at low glucose without affecting the response to high glucose. It was now assumed that the enzyme worked in the opposite direction and thus lowered cell glutamate content (25).

Glutamine markedly increases islet glutamate content (20, 26, 27) but does not induce insulin secretion unless GDH is concomitantly activated by leucine or its non-metabolized analogue BCH (28, 29). This lack of effect on insulin secretion is explained by the inability of glutamine alone to produce enough ATP to close K+-ATP channels, depolarize the membrane, and raise [Ca2+]i in beta -cells (26, 29-31).

It would not be correct, however, to use the foregoing data, all obtained under conditions testing the triggering pathway of insulin secretion, to refute the glutamate hypothesis, which clearly restricts the role of glutamate to the amplifying pathway (16). Virtually nothing has been done to test the hypothesis adequately. Islet glutamate content has not been measured under conditions where the amplifying pathway was being studied. Moreover, the available insulin secretion data are limited to two reports showing that in a medium containing 30-50 mM K+, 250 µM diazoxide, and no glucose, 10-20 mM glutamine has little or no effect on insulin secretion, unless, again, if GDH, is activated (9, 32). This poor effect of glutamine alone has tentatively been ascribed to an alleged alkalinization of the beta -cell cytoplasm (16). The explanation deserves verification because an independent study suggested that glucose-induced priming of insulin secretion, which is thought to be mediated by the amplifying pathway (13), is indeed inhibited by beta -cell alkalinization (33).

In the present study, mouse islets were thus incubated or perifused under depolarizing conditions (high K+ or sulfonylurea) to study the effects of glucose, glutamine, and BCH to activate GDH, on the amplifying pathway of insulin secretion. Glutamate was measured in the same islets, and possible changes in [Ca2+]i and pHi were checked for in parallel experiments. A control series of tests was also performed with rat islets to validate our conclusions in a second species.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Solutions and Reagents-- The control medium was a bicarbonate-buffered solution containing (mM): NaCl, 120; KCl, 4.8; CaCl2, 2.5; MgCl2, 1.2; and NaHCO3, 24. It was maintained under O2/CO2 (94:6) to a pH of 7.4, and it contained 10 mM glucose and 1 mg/ml bovine serum albumin. A similar solution was used as test medium after adjustment of the glucose concentration and addition of the studied substances. When the concentration of KCl was increased to 30 mM, that of NaCl was decreased accordingly; otherwise the substances were added without osmotic compensation.

Glutamine (Microselect) was from Fluka (Buchs, Switzerland), diazoxide was a gift of Schering-Plough Avondale (Rathdrum, Ireland), BCH, tolbutamide, and glibenclamide were from Sigma. Other reagents were from Merck AG (Darmstadt, Germany).

Preparations-- The experiments were performed with overnight-cultured mouse islets and freshly isolated rat islets. Mouse islets were aseptically isolated by collagenase digestion of the pancreas of female NMRI mice (25-30 g) followed by hand selection. The islets were then cultured for about 18 h in RPMI 1640 medium containing 10 mM glucose, 10% heat-inactivated fetal calf serum, 100 IU/ml penicillin, and 100 µg/ml streptomycin. Rat islets were isolated by collagenase digestion of the pancreas of male Wistar rats (300-320 g). They were used immediately after isolation.

Measurements of Insulin Secretion and Islet Glutamate Content-- Cultured mouse islets and freshly isolated rat islets were preincubated for 60 min at 37 °C in control medium containing 10 mM glucose. They were then distributed in batches of 12, at room temperature, in control medium containing 3 mM glucose. Each batch was transferred into an Eppendorf conical tube containing 750 µl of test medium and incubated for 60 min at 37 °C. At the end of the incubation, the tubes were gently (10 s) centrifuged, 700 µl of medium were removed and saved for insulin measurement, and 700 µl of cold control medium were added. After gentle shaking to ensure good rinsing of the islets, the tubes were again briefly centrifuged, and 700 µl of medium were removed and discarded. On the islets and the remaining 50 µl of medium, 200 µl of an acid-ethanol mixture (34) were added. The samples were then sonicated and frozen until glutamate assay. Blanks without islets were run in parallel and treated exactly as samples.

Cultured mouse islets were also studied using a dynamic system of perifusion (35). After preincubation as described above and distribution in batches of 15, the islets were transferred into perifusion chambers. They were then perifused at 37 °C with test solutions described in the figure legends. The effluent fractions were collected at 2-min intervals and saved for insulin assay. At the end of the experiment the perifusion was stopped, the chamber was opened, and the islets were recovered, rinsed twice in cold control medium, and transferred in Eppendorf tubes with 50 µl of medium. After addition of 200 µl of acid-ethanol mixture, the samples were processed as above.

Measurements of Islet [Ca2+]i and pHi-- Cultured mouse islets were loaded with the Ca2+ indicator fura-PE3 (2 µM, 3 h) or the pH indicator BCECF (2',7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein (0.5 µM, 1 h) in control medium containing 10 mM glucose. Loaded islets were then transferred (3-4 at a time) into the perifusion chamber of a spectrofluorimetric system with which [Ca2+]i and pHi were measured as described previously (36, 37).

Insulin and Glutamate Assays-- Insulin in the incubation or perifusion medium was measured by radioimmunoassay using rat insulin as a standard. Glutamate in the islet extracts was measured by an high performance liquid chromatography system (Beckman) using ortho-phthaldialdehyde (OPA) derivatization. 40 µl of islet extract were diluted 5-fold with water, mixed with 70 µl of an OPA-2-mercaptoethanol-derivatizing solution, and injected 1 min later using a Gilson automatic sample injector (model 231-401) with a fixed 20-min injection cycle. The separation and identification of glutamate was performed as described previously, with minor modifications (38, 39). The peak area of glutamate was determined with the Gold system (Beckman), and the glutamate concentration was calculated by comparison with external standards treated like samples. Only traces or no glutamate was detected in blanks without islets, except when the incubation or perifusion medium contained glutamine. All commercial preparations of glutamine tested contained small quantities of glutamate. The contamination by exogenous glutamate after rinsing was about 10% of the islet glutamate content and was corrected for.

Presentation of Results-- All experiments have been performed with islets from 3-6 different preparations. Results are presented as means ± S.E. The statistical significance of differences between means was assessed by analysis of variance followed by a Newman-Keuls test for multiple comparisons and by Student's t test in a few cases. Differences were considered significant at p < 0.05.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Study of the Amplifying Pathway in Incubated Mouse Islets-- In the first series of experiments, batches of mouse islets were incubated with 2 µM glibenclamide, a concentration of sulfonylurea that completely blocks K+-ATP channels (3, 40, 41). Insulin secretion was stimulated in the absence of glucose (1.39 ± 0.12 ng·h-1·islet-1 versus 0.27 ± 0.02 ng·h-1·islet-1 without glibenclamide) and was further increased by the presence of 3 mM glucose (2.00 ± 0.28 ng·h-1·islet-1, p < 0.05) and 20 mM glucose (7.41 ± 0.61 ng·h-1·islet-1, p < 0.001) (Fig. 1). This additional effect of glucose reflects the amplifying action of the sugar (1). The glutamate content of the islets incubated in 0 mM glucose and 2 µM glibenclamide averaged 4.67 ± 0.45 pmol·islet-1. It increased 1.4-fold (p < 0.05) and 2.6-fold (p < 0.001) in the presence of 3 and 20 mM glucose, respectively (Fig. 1). Thus, there was a parallel (but not proportional) increase in islet glutamate content and insulin secretion under these conditions.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 1.   Insulin secretion and glutamate content in mouse islets incubated in the presence of a high concentration of glibenclamide. Batches of 12 mouse islets were incubated in the presence of 2 µM glibenclamide and 0, 3, or 20 mM glucose (G0, G3, G20). The medium also contained 0.5 or 2 mM glutamine (Gln), 10 mM BCH, or the combination of 2 mM Gln and 10 mM BCH as indicated. The results show the amount of insulin secreted after 1 h of incubation (open columns) and the glutamate content of the same islets at the end of the incubation (filled columns). In the box on top of each panel is given the correlation coefficient between insulin secretion and the islet glutamate content. Values are means ± S.E. for 8-11 batches of islets from four separate preparations. *, p < 0.05 or less versus controls at the same glucose concentration (i.e. within each panel). NS, not significant.

When glutamine (0.5 and 2 mM) was added to the medium containing 2 µM glibenclamide, a concentration-dependent increase in islet glutamate content was observed (Fig. 1). As compared with control islets, this increase was particularly large (3- to 5-fold) in 0 and 3 mM glucose, whereas insulin secretion was at the most doubled by 2 mM glutamine in 3 mM glucose (Fig. 1). There was no significant effect of glutamine on insulin secretion in the other conditions. For example, the 2-fold increase in glutamate content induced by 0.5 mM glutamine in 0 or 3 mM glucose, or by 2 mM glutamine in 20 mM glucose was not accompanied by significant changes in insulin secretion (Fig. 1). The situation was strikingly different in the presence of BCH, an activator of glutamate dehydrogenase (28, 42). BCH lowered the islet glutamate content by about 50% in 0 and 3 mM glucose while increasing insulin secretion 2-fold (Fig. 1). When BCH and glutamine were combined, the elevation of islet glutamate normally produced by glutamine was attenuated, but insulin secretion was amplified except in 20 mM glucose, where BCH lowered islet glutamate without affecting insulin secretion (Fig. 1).

A second approach to studying the amplifying action of glucose on insulin secretion consists in holding K+-ATP channels open with diazoxide and elevating beta -cell [Ca2+]i by depolarizing the membrane with 30 mM K+ (8). Under these conditions, insulin secretion was stimulated even in the absence of glucose (2.29 ± 0.17 ng·h-1·islet-1) and was further increased by 3 mM glucose (3.31 ± 0.25 ng·h-1·islet-1, p < 0.05) and 20 mM glucose (8.26 ± 0.43 ng·h-1·islet-1, p < 0.001) (Fig. 2). The glutamate content of the islets incubated in 0 mM glucose and 30 mM K+ averaged 6.15 ± 0.53 pmol·islet-1. It increased 35% (p < 0.05 by Student's t test only) and 132% (p < 0.001) in the presence of 3 and 20 mM glucose, respectively (Fig. 2).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 2.   Insulin secretion and glutamate content in mouse islets incubated in the presence of a depolarizing concentration of K+. Batches of 12 mouse islets were incubated in the presence of 30 mM KCl, 250 µM diazoxide, and 0, 3, or 20 mM glucose (G0, G3, G20). The medium also contained 0.5 or 2 mM glutamine (Gln), 10 mM BCH, or the combination of 2 mM Gln and 10 mM BCH as indicated. The results show the amount of insulin secreted after 1 h of incubation (open columns) and the glutamate content of the same islets at the end of the incubation (filled columns). In the box on top of each panel is given the correlation coefficient between insulin secretion and the islet glutamate content. Values are means ± S.E. for 10-15 batches of islets from five separate preparations. *, p < 0.05 or less versus controls at the same glucose concentration (i.e. within each panel). NS, not significant.

Glutamine consistently elevated islet glutamate content above controls (from 35% by 0.5 mM glutamine in 20 mM glucose to 400% by 2 mM glutamine in 0 mM glucose). However, the only significant effect on insulin secretion was a 50% increase produced by 2 mM glutamine in 0 mM glucose (Fig. 2). Again, the contrast with BCH was striking. BCH alone amplified insulin secretion (50-70%) at 0 and 3 mM glucose while lowering islet glutamate by 65%. When BCH was combined with glutamine the rise in islet glutamate was attenuated, but the increase in insulin secretion was even larger (Fig. 2).

When insulin secretion and the islet glutamate content were compared in the different experimental conditions tested at each glucose concentration (each panel of Figs. 1 and 2), no correlation was ever found. However, when the analysis focused on the differences between 0, 3, and 20 mM glucose, a significant correlation was found for control islets and for islets incubated in the presence of BCH (Fig. 3). There was no correlation in the presence of 0.5 (Fig. 3) or 2 mM glutamine alone (not shown). Correlative arguments for and against the glutamate hypothesis can thus be obtained with this commonly used technique of incubation. The weakness of the approach is that the correlation is made between insulin secreted during the whole incubation and the concentration of an islet metabolite at one single late time point. We therefore also used a dynamic system of perifusion to permit closer comparison of the islet glutamate content with the actual rate of insulin secretion.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 3.   Comparison of the effects of glucose on insulin secretion and islet glutamate content in incubated mouse islets. These results, taken from Figs. 1 and 2, were obtained in the presence of 2 µM glibenclamide (open symbols) or 30 mM K+ and 250 µM diazoxide (filled symbols) and either no additional test substance (Controls: open circle , ), 10 mM BCH (, black-square) or 0.5 mM glutamine (Gln: Delta , black-triangle). For each symbol, from bottom to top, the results are in 0, 3, and 20 mM glucose. Values are means ± S.E.; NS, not significant.

Study of the Amplifying Pathway in Perifused Mouse Islets-- The islets were perifused with a medium containing 7 mM glucose and a concentration of tolbutamide (500 µM) that also completely blocks K+-ATP channels (3, 40, 41). Under these conditions the rate of insulin secretion slightly declined with time (Fig. 4A) but remained well above (5-7-fold) the basal rate in the presence of 3 mM glucose alone. Addition of 0.5 mM glutamine to the medium increased the islet glutamate content 2.2-fold without influencing insulin secretion (Fig. 4, A and B). In contrast, BCH lowered islet glutamate and increased insulin secretion ~4-fold. The combination of glutamine and BCH increased insulin secretion 5-fold without changing islet glutamate as compared with controls. Raising the concentration of glucose from 7 to 20 mM also strongly amplified insulin secretion without changing islet glutamate. Thus, there was no correlation between islet glutamate content and the actual rate of insulin secretion at the same moment (Fig. 4B).


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 4.   Insulin secretion and glutamate content in mouse islets perifused in the presence of a high concentration of tolbutamide. The islets were perifused with a medium containing 7 mM glucose and 500 µM tolbutamide (G7-Tolb 500 µM). An initial stabilization period of 40 min is not shown. 10 min after collection of the effluent fractions was started, a test substance was applied except in the control group (O). This test substance was a rise of the glucose concentration to 20 mM (G20), glutamine 0.5 mM (Gln 0.5), BCH 5 mM (BCH 5), or the combination of Gln and BCH. A, actual rates of insulin secretion in three experimental groups. B, average rate of insulin secretion computed over the last 10 min (shaded area in A) and glutamate content of the same islets removed from the chambers at 80 min. Values are means ± S.E. for eight experiments in which the different protocols were tested in parallel, with islets from the same preparation. *, p < 0.05 or less versus controls without test substance. NS, not significant.

We also compared the influence of the different test agents on islet [Ca2+]i and pHi (Fig. 5). During continuous depolarization with either a high concentration of sulfonylurea or a high concentration of extracellular K+, apparent islet [Ca2+]i slowly but steadily increases at a rate of approximately 2 nM/min (43). This trend must be taken into account when assessing possible effects of test agents. A similar increase was observed in this series during perifusion of control islets with 7 mM glucose and 500 µM tolbutamide (Fig. 5, A and B). For all islets tested under these conditions (n = 65), i.e. during the 5-min period preceding application of test substances, average [Ca2+]i was 214 ± 2 nM, well above basal [Ca2+]i in 3 mM glucose alone (~70-90 nM, data not shown). Glutamine (0.5 mM) did not affect [Ca2+]i, whereas BCH alone, BCH combined with glutamine, and a rise in the glucose concentration to 20 mM all produced similar changes, described previously for glucose (43) and characterized by a small transient decrease followed by an increase slightly above control values (Fig. 5, A and B).


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 5.   Impact of several test agents on [Ca2+]i and pHi in mouse islets perifused in the presence of a high concentration of tolbutamide. The islets were perifused with a medium containing 7 mM glucose and 500 µM tolbutamide (G7-Tolb 500 µM). An initial stabilization period of 20 min is not shown. 10 min after the recording was started, a test substance was applied except in the control group. This test substance was a rise of the glucose concentration to 20 mM (G20), 0.5 mM glutamine (Gln 0.5), 5 mM BCH (BCH 5), or the combination of Gln and BCH. A and C, actual changes in [Ca2+]i and pHi in control islets (thin lines) or in test islets (thick lines). B and D, difference in average [Ca2+]i or pHi between 40-45 min and 25-30 min (shaded periods), i.e. during and just before application of the test substance. Values are means ± S.E. for 13 islets from three preparations for [Ca2+]i experiments and for 11 islets from three preparations for pHi experiments. *, p < 0.001 versus controls without test substance.

The impact of the same substances on islet pHi is shown in Fig. 5, C and D. For all islets, pHi in the presence of 7 mM glucose and 500 µM tolbutamide, i.e. during the 5-min period before application of any test agent, averaged 6.96 ± 0.01 (n = 55). Addition of glutamine alone had no effect, whereas BCH (either alone or in combination with glutamine) and high glucose caused a slight increase in pHi (Fig. 5).

When perifused mouse islets are stimulated with 30 mM K+ in the presence of 3 mM glucose and diazoxide, an initial large peak of insulin secretion is followed by a progressive decline of the secretory rate (9). Only this decline is shown in Fig. 6. Raising the glucose concentration to 20 mM stopped this spontaneous evolution and amplified insulin secretion while augmenting islet glutamate levels. Addition of 0.5 or 2 mM glutamine to the medium failed to influence insulin secretion, although islet glutamate was increased severalfold. In contrast, BCH alone or combined with 0.5 mM glutamine markedly increased insulin secretion while lowering islet glutamate content (Fig. 6). Thus, there was no correlation between islet glutamate and the rate of insulin secretion at the same moment (Fig. 6).


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 6.   Insulin secretion and glutamate content in mouse islets perifused in the presence of a depolarizing concentration of K+. The islets were perifused with a medium containing 3 mM glucose, 30 mM KCl, and 250 µM diazoxide. An initial period of 30 min is not shown. 10 min after collection of the effluent was started, different test substances were applied except in the control group (O). These test substances were a rise of the glucose concentration to 20 mM (G20), 0.5 or 2 mM glutamine (Gln 0.5, Gln 2), 5 mM BCH (BCH 5), and the combination of BCH and 0.5 mM glutamine (BCH Gln). A, actual rates of insulin secretion in three experimental groups. B, average rate of insulin secretion computed over the last 10 min (shaded area in A) and glutamate content of the same islets removed from the chambers at 70 min. Values are means ± S.E. for seven experiments in which the different protocols were tested in parallel, with islets from the same preparation. *, p < 0.05 or less versus controls without test substance. NS, not significant.

During steady state depolarization with 30 mM K+ in the presence of 3 mM glucose and 250 µM diazoxide, [Ca2+]i was elevated, averaging 286 ± 4 nM for the period of 25-30 min in all islets (n = 84). As already mentioned above, [Ca2+]i slowly increased with time under control conditions (Fig. 7). Raising the concentration of glucose to 20 mM caused a rapid decrease in [Ca2+]i followed by an incomplete recovery so that [Ca2+]i remained below control values during the period of 40-45 min (Fig. 7, A and B). A similar biphasic decrease in [Ca2+]i occurred upon addition of BCH alone or together with 0.5 mM glutamine. In contrast, glutamine alone, at 0.5 or 2 mM, was without effect on [Ca2+]i (Fig. 7, A and B).


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 7.   Impact of several test agents on [Ca2+]i and pHi in mouse islets perifused in the presence of a depolarizing concentration of K+. The islets were perifused with a medium containing 3 mM glucose, 30 mM KCl, and 250 µM diazoxide. An initial stabilization period of 20 min is not shown. 10 min after the recording was started, a test substance was applied except in the control group. This test substance was a rise of the glucose concentration to 20 mM (G20), 0.5 or 2 mM glutamine (Gln 0.5, Gln 2), 5 mM BCH (BCH 5), or the combination of BCH and 0.5 mM glutamine (BCH Gln). A and C, actual changes in [Ca2+]i and pHi in control islets (thin lines) and in test islets (thick lines). B and D, differences in average [Ca2+]i or pHi between 40-45 min and 25-30 min (shaded periods), i.e. during and just before application of the test substance. Values are means ± S.E. for 14 islets from four preparations for [Ca2+]i experiments and 11 islets from three preparations for pHi experiments. *, p < 0.001 versus controls without test substance.

In these depolarized islets, pHi averaged 6.87 ± 0.01 (n = 66) during the period of 25-30 min (Fig. 7). Raising the glucose concentration from 3 to 20 mM increased pHi as reported previously (37). Similar changes were produced by BCH alone and the combination of BCH and 0.5 mM glutamine, whereas glutamine alone had no significant effect (Fig. 7, C and D).

Although 0.5 mM glutamine was generally found not to amplify insulin secretion, a significant effect was disclosed when the islets were subjected to the influence of the different test agents throughout the experiment, and the stimulation with 30 mM K+ was applied after 50 min only (Fig. 8). The initial rate of insulin secretion was low and independent of the test agent because of the presence of diazoxide (Fig. 8A). Under these conditions, the presence of 0.5 mM glutamine in the medium containing 3 mM glucose resulted in a 2-fold increase in K+-induced insulin secretion, whereas islet glutamate was tripled (Fig. 8, A and B). However, 10 mM glucose alone tripled insulin secretion while increasing islet glutamate by 1.5-fold only. At 10 mM glucose, 0.5 mM glutamine doubled islet glutamate without influencing insulin secretion. Under the same experimental conditions, BCH lowered glutamate content in 3 mM glucose but did not increase insulin secretion unless it was combined with exogenous glutamine. In 10 mM glucose the decrease in islet glutamate induced by BCH had no impact on insulin secretion (Fig. 8, A and B).


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 8.   Insulin secretion and glutamate content in mouse islets stimulated by a depolarizing concentration of K+. The islets were perifused with a medium containing 250 µM diazoxide and either 3 or 10 mM glucose (G3, G10) throughout. Except in the control group, the medium also contained 0.5 mM glutamine (Gln 0.5), 5 mM BCH (BCH 5), or the combination of Gln and BCH (BCH Gln). An initial stabilization period of 40 min is not shown. 10 min after collection of the effluent was started, the concentration of KCl was raised from 4.8 to 30 mM. A, actual rates of insulin secretion in three experimental groups. B, average rate of insulin secretion computed over the last 10 min (shaded area in A) and glutamate content of the same islets removed from the chambers at 80 min. Values are means ± S.E. for eight experiments in which the different protocols were tested in parallel, with islets from the same preparation. *, p < 0.05 or less versus controls without test substance. NS, not significant.

Study of the Amplifying Pathway in Incubated Rat Islets-- It has been argued that glutamate metabolism and effects might be different in mouse and rat beta -cells (16). The potential role of glutamate in the amplification of insulin secretion was therefore tested with rat islets during depolarization with 30 mM K+ in the presence of diazoxide (Fig. 9). K+-induced insulin secretion in 0 mM glucose amounted to 1.34 ± 0.08 ng·h-1·islet-1. It was increased 45 (p < 0.05) and 310% (p < 0.001) by 3 and 20 mM glucose, respectively. Simultaneously, the islet glutamate content (7.19 ± 0.34 pmol·islet-1) was augmented 45 and 95% (p < 0.001), respectively. Glutamine (2 mM) markedly (4- to 7-fold) elevated islet glutamate without influencing insulin secretion. In 0 and 3 mM glucose, BCH alone lowered islet glutamate by 35-40% (p < 0.001 by Student's t test) and increased insulin secretion. The amplification of insulin secretion was not significantly larger when BCH was combined with glutamine, although the islet glutamate content was 5- to 7-fold higher (Fig. 9). In 20 mM glucose, BCH lowered islet glutamate without changing insulin secretion. These results obtained in rat islets are thus essentially similar to those in mouse islets, with no correlation between islet glutamate and insulin secretion.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 9.   Insulin secretion and glutamate content in rat islets incubated in the presence of a depolarizing concentration of K+. Batches of 12 rat islets were incubated in the presence of 30 mM KCl, 250 µM diazoxide, and 0, 3, or 20 mM glucose (G0, G3, G20). The medium also contained 2 mM glutamine (Gln), 10 mM BCH, or the combination of 2 mM Gln and 10 mM BCH as indicated. The results show the amount of insulin secreted after 1 h of incubation (open columns) and the glutamate content of the same islets at the end of the incubation (filled columns). In the box at the top of each panel is given the correlation coefficient between insulin secretion and the islet glutamate content. Values are means ± S.E. for 8-11 batches of islets from four separate preparations. *, p < 0.05 or less versus controls at the same glucose concentration (i.e. within each panel). NS, not significant.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

When the medium did not contain glutamine or BCH, the glutamate levels of our mouse or rat islets ranged from 5 to 15 pmol·islet-1, i.e. 1.7 to 3 mM for an intracellular space of 3 nl/islet (26, 44). These values correspond well with those measured by others in rodent islets (19, 20, 27). They are slightly higher than those in human islets (17) and INS-1E cells (22) and much higher than those in INS-1 cells (17).

We confirm that glutamine markedly increases islet glutamate levels in rat islets (20, 26, 27, 45), and we show that it has the same effect in mouse islets, which can be explained by the activity of the glutaminase (27). We also establish that activation of GDH by BCH lowers islet glutamate content not only in the presence of exogenous glutamine (20, 45) but also in its absence. Because this decrease in islet glutamate by BCH was seen at all glucose concentrations it appears that the flux controlled by GDH consistently goes from glutamate to alpha -ketoglutarate. Yet, in contrast with several reports (18-20), we observed that glucose increased glutamate levels in rat and mouse islets. This effect was concentration-dependent (~40% at 3 mM and ~120% at 20 mM glucose) but clearly was less than the 5-fold increase reported for human islets and INS cells (17). It is also noteworthy that glucose did not affect the elevation of islet glutamate levels induced by exogenous glutamine but retained an increasing effect when GDH was activated by BCH, at least in the mouse.

This study was not designed to investigate the mechanisms by which glucose might affect glutamate metabolism, but the following explanation is tentatively proposed. The increase in islet glutamate that glucose produces in the absence of glutamine, whether GDH is activated by BCH or not, may result from an inhibition of GDH by the high-GTP and low-ADP environment (31, 46) characteristic of glucose-stimulated islets (47). In the presence of exogenous glutamine, reduction of the flux through GDH has no impact on the already high glutamate levels, perhaps because of a decrease in glutaminase activity (45). This interpretation is fully compatible with recent studies of leucine-induced insulin secretion in isolated mouse islets (31) and in patients with an activating mutation of GDH (48).

We emphasize again that our experiments were carried out under conditions selected to study the amplifying action of glucose and other agents on insulin secretion. The paradigm is that beta -cell [Ca2+]i is steadily elevated independently from the tested agents and is little affected by these agents (1). Because the latter condition is difficult to achieve direct control is important, in particular when novel conditions are being tested. The slight decrease in [Ca2+]i produced by high glucose in the presence of high K+ and diazoxide and the small increase produced in the presence of a maximally effective concentration of sulfonylurea are similar to those described and discussed previously (43). This study shows that BCH alone or with glutamine had a similar or slightly smaller impact on [Ca2+]i than that of glucose, whereas glutamine alone did not change [Ca2+]i. One can thus be confident that the amplifying pathway of insulin secretion, as opposed to the triggering pathway that involves a stimulus-induced large increase in [Ca2+]i from basal values, was being studied in the present experiments (1). It is also clear that differences in the effects of the tested agents on insulin secretion cannot be attributed to markedly divergent actions on [Ca2+]i.

In agreement with a number of studies reviewed recently (1, 13), glucose amplified insulin secretion from rat and mouse islets in a concentration-dependent manner with a significant effect already at 3 mM. In incubated mouse islets, the amplification of insulin secretion by glucose was accompanied by an elevation of islet glutamate content such that a tight, direct correlation was found between the two variables, both in the absence and presence of BCH, i.e. at very different glutamate concentrations. These results, therefore, confirm that insulin secretion may be directly correlated with cellular glutamate under selected conditions (22). However, a correlation between a cumulative event (insulin secretion) and a metabolic situation at a single time point (islet glutamate concentration) has a limited significance. Moreover, correlative evidence is never sufficient to establish a causal link. In fact the arguments against a role of glutamate predominate.

Exogenous glutamine (0.5 and 2 mM) consistently increased islet glutamate levels, generally to a larger extent than did glucose, but amplified insulin secretion weakly under three conditions only. In the majority of situations (14/17), glutamine failed to influence insulin secretion. Importantly, the inefficacy of glutamine on insulin secretion was observed in the presence of 3 or 7 mM glucose, i.e. under optimal conditions where metabolism of the sugar provides basal ATP to sustain Ca2+-induced exocytosis and where the amplifying pathway is far from being maximally activated (1). We therefore conclude that a rise in islet glutamate content is not a sufficient signal to amplify insulin secretion.

In the presence of exogenous glutamine glucose strongly amplified insulin secretion, although the elevated islet glutamate levels did not change. We therefore conclude that intracellular glutamate is at best a permissive signal and that glucose produces one or several other signals that increase the action of Ca2+ on exocytosis. Because similar insulin secretion sometimes occurred at very different intracellular glutamate levels, we can also exclude the remote possibility that the amplifying action of the amino acid would be restricted to a narrow range of concentrations.

In the absence of exogenous glutamine, BCH lowered islet glutamate to below basal values but amplified insulin secretion (0-7 mM glucose) or did not affect it (10-20 mM glucose). Combination of BCH and glutamine attenuated the elevation of glutamate produced by the latter alone but increased or did not affect (in high glucose) insulin secretion. Changing the glucose concentration from 7 to 20 mM in the presence of tolbutamide also amplified insulin secretion 3-fold without modifying islet glutamate. We therefore conclude that an increase in intracellular glutamate is not a necessary signal for the amplification of insulin secretion.

Exogenous NH4Cl is known to impair the amplification of insulin secretion by glucose (9). It has therefore been argued that glutamine is an inadequate tool to test the glutamate hypothesis because NH4 production by the metabolism of the amino acid in beta -cells (26) might also blunt the amplifying pathway through an alkalinization of the cytoplasm or other mechanisms (16). These concerns are completely ungrounded at least when glutamine is used at a close to physiological concentration as in this study. First, under no condition did glutamine impair insulin secretion or impair the amplification by glucose. Second, we have reported previously that raising [Ca2+]i in beta -cells by high K+ or tolbutamide lowers pHi at low glucose and that a subsequent rise in glucose or the addition of alpha -ketoisocaproate (two conditions causing amplification of insulin secretion) (9), increases pHi (37, 49). We now show that BCH and the combination of BCH with glutamine produce a similar alkalinization, whereas glutamine alone has no effect. Our findings, therefore, contradict the predictions and validate the use of glutamine to test the hypothesis. Another important observation is that only those fuels which increase pHi also amplify insulin secretion. This correlation is clearly insufficient to establish any causal relationship, but at least it makes untenable the idea that a decrease in intracellular pH is a major contributor of the amplifying and related actions of glucose and other nutrients (33).

In conclusion, glucose augments glutamate content in mouse and rat islets under conditions where the sugar amplifies insulin secretion. However, this increase is neither sufficient nor necessary. Numerous dissociations between changes in islet glutamate and insulin secretion allow us to refute the idea that an increase in beta -cell glutamate is an important messenger in the amplification of insulin secretion by glucose.

    ACKNOWLEDGEMENTS

We thank F. Knockaert and R. Puech for technical assistance and V. Lebec for editorial help.

    FOOTNOTES

* This work was supported by Grant 3.4552.98 from the Fonds de la Recherche Scientifique Médicale (Brussels), by Grant ARC 00/05-260 from the General Direction of Scientific Research of the French Community of Belgium, by the Interuniversity Poles of Attraction Program P5/3/20 Federal Office for Scientific, Technical, and Cultural Affairs from Belgium, and by the Centre National de la Recherche Scientifique (Paris).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Unité d'Endocrinologie et Métabolisme, UCL 55.30, Ave. Hippocrate 55, B-1200 Brussels, Belgium. Tel.: 32-2-7645529; Fax: 32-2-7645532; E-mail: henquin@endo.ucl.ac.be.

Published, JBC Papers in Press, June 26, 2002, DOI 10.1074/jbc.M205326200

    ABBREVIATIONS

The abbreviations used are: K+-ATP channel, ATP-sensitive K+ channel; [Ca2+]i, cytoplasmic Ca2+ concentration; GDH, glutamate dehydrogenase; GAD, glutamate decarboxylase; pHi, cytoplasmic pH; BCH, 2-amino 2-norbornane carboxylic acid.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Henquin, J. C. (2000) Diabetes 49, 1751-1760[Abstract]
2. Rorsman, P. (1997) Diabetologia 40, 487-495[CrossRef][Medline] [Order article via Infotrieve]
3. Ashcroft, F. M., and Gribble, F. M. (1999) Diabetologia 42, 903-919[CrossRef][Medline] [Order article via Infotrieve]
4. Seino, S., Iwanaga, T., Nagashima, K., and Miki, T. (2000) Diabetes 49, 311-318[Abstract]
5. Newgard, C. B., and Matschinsky, F. M. (2001) in Handbook of Physiology (Jefferson, J. , and Cherrington, A., eds), Vol. 2 , pp. 125-152, Oxford University Press, London
6. Schuit, F. C., Huypens, P., Heimberg, H., and Pipeleers, D. G. (2001) Diabetes 50, 1-11[Abstract/Free Full Text]
7. Gilon, P., Ravier, M. A., Jonas, J. C., and Henquin, J. C. (2002) Diabetes 51 Suppl. 1, S144-S151[Abstract/Free Full Text]
8. Gembal, M., Gilon, P., and Henquin, J. C. (1992) J. Clin. Invest. 89, 1288-1295[Medline] [Order article via Infotrieve]
9. Gembal, M., Detimary, P., Gilon, P., Gao, Z. Y., and Henquin, J. C. (1993) J. Clin. Invest. 91, 871-880[Medline] [Order article via Infotrieve]
10. Sato, Y., Aizawa, T., Komatsu, M., Okada, N., and Yamada, T. (1992) Diabetes 41, 438-443[Abstract]
11. Sato, Y., and Henquin, J. C. (1998) Diabetes 47, 1713-1721[Abstract]
12. Corkey, B. E., Deeney, J. T., Yaney, G. C., Tornheim, K., and Prentki, M. (2000) J. Nutr. 130, 299S-304S[Abstract/Free Full Text]
13. Komatsu, M., Sato, Y., Aizawa, T., and Hashizume, K. (2001) Endocr. J. 48, 275-288[Medline] [Order article via Infotrieve]
14. Eto, K., Yamashita, T., Tsubamoto, Y., Terauchi, Y., Hirose, K., Kubota, N., Yamashita, S., Taka, J., Satoh, S., Sekihara, H., Tobe, K., Iino, M., Noda, M., Kimura, S., and Kadowaki, T. (2002) Diabetes 51, 87-97[Abstract/Free Full Text]
15. Lu, D., Mulder, H., Zhao, P., Burgess, S. C., Jensen, M. V., Kamzolova, S., Newgard, C. B., and Sherry, A. D. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 2708-2713[Abstract/Free Full Text]
16. Wollheim, C. B., and Maechler, P. (2002) Diabetes 51 Suppl. 1, S37-S42[Abstract/Free Full Text]
17. Maechler, P., and Wollheim, C. B. (1999) Nature 402, 685-689[CrossRef][Medline] [Order article via Infotrieve]
18. Danielsson, A., Hellman, B., and Idahl, L. A. (1970) Horm. Metab. Res. 2, 28-31[Medline] [Order article via Infotrieve]
19. Gylfe, E., and Hellman, B. (1974) Endocrinology 94, 1150-1156[Abstract/Free Full Text]
20. MacDonald, M. J., and Fahien, L. A. (2000) J. Biol. Chem. 275, 34025-34027[Abstract/Free Full Text]
21. Sener, A., Conget, I., Rasschaert, J., Leclercq-Meyer, V., Villanueva- Peñacarrillo, M. L., Valverde, I., and Malaisse, W. J. (1994) Am. J. Physiol. 267, E573-E584[Abstract/Free Full Text]
22. Rubi, B., Ishihara, H., Hegardt, F. G., Wollheim, C. B., and Maechler, P. (2001) J. Biol. Chem. 276, 36391-36396[Abstract/Free Full Text]
23. Shi, Y., Kanaani, J., Menard-Rose, V., Ma, Y. H., Chang, P. Y., Hanahan, D., Tobin, A., Grodsky, G., and Baekkeskov, S. (2000) Am. J. Physiol. Endocrinol. Metab. 279, E684-E694[Abstract/Free Full Text]
24. Maechler, P., Antinozzi, P. A., and Wollheim, C. B. (2000) IUBMB Life 50, 27-31[CrossRef][Medline] [Order article via Infotrieve]
25. Tanizawa, Y., Nakai, K., Sasaki, T., Anno, T., Ohta, Y., Inoue, H., Matsuo, K., Koga, M., Furukawa, S., and Oka, Y. (2002) Diabetes 51, 712-717[Abstract/Free Full Text]
26. Malaisse, W. J., Sener, A., Carpinelli, A. R., Anjaneyulu, K., Lebrun, P., Herchuelz, A., and Christophe, J. (1980) Mol. Cell. Endocrinol. 20, 171-189[CrossRef][Medline] [Order article via Infotrieve]
27. Michalik, M., Nelson, J., and Erecinska, M. (1992) Metabolism 41, 1319-1326[CrossRef][Medline] [Order article via Infotrieve]
28. Sener, A., and Malaisse, W. J. (1980) Nature 288, 187-189[CrossRef][Medline] [Order article via Infotrieve]
29. Panten, U., Zielmann, S., Langer, J., Zünkler, B. J., and Lenzen, S. (1984) Biochem. J. 219, 189-196[Medline] [Order article via Infotrieve]
30. Meissner, H. P., and Henquin, J. C. (1983) Diabetes 1982, ICS 600, Excerpta Medica, pp. 353-360, Amsterdam
31. Gao, Z. Y., Li, G., Najafi, H., Wolf, B. A., and Matschinsky, F. M. (1999) Diabetes 48, 1535-1542[Abstract]
32. Yamada, S., Komatsu, M., Sato, Y., Yamauchi, K., Aizawa, T., and Hashizume, K. (2001) Endocr. J. 48, 391-395[Medline] [Order article via Infotrieve]
33. Gunawardana, S. C., and Sharp, G. W. G. (2002) Diabetes 51, 105-113[Abstract/Free Full Text]
34. Detimary, P., Jonas, J. C., and Henquin, J. C. (1995) J. Clin. Invest. 96, 1738-1745[Medline] [Order article via Infotrieve]
35. Henquin, J. C. (1978) Nature 271, 271-273[CrossRef][Medline] [Order article via Infotrieve]
36. Gilon, P., and Henquin, J. C. (1992) J. Biol. Chem. 267, 20713-20720[Abstract/Free Full Text]
37. Shepherd, R. M., and Henquin, J. C. (1995) J. Biol. Chem. 270, 7915-7921[Abstract/Free Full Text]
38. Pin, J. P., Weiss, S., Sebben, M., Kemp, D. E., and Bockaert, J. (1986) J. Neurochem. 47, 594-603[Medline] [Order article via Infotrieve]
39. Bertrand, G., Puech, R., Loubatieres-Mariani, M. M., and Bockaert, J. (1995) Am. J. Physiol. 269, E551-E556[Abstract/Free Full Text]
40. Zünkler, B. J., Lenzen, S., Männer, K., Panten, U., and Trube, G. (1988) Arch. Pharmacol. 337, 225-230
41. Aguilar-Bryan, L., Clement, J. P., Gonzalez, G., Kunjilwar, K., Babenko, A., and Bryan, J. (1998) Physiol. Rev. 78, 227-245[Abstract/Free Full Text]
42. Panten, U., and Langer, J. (1981) Biochem. J. 198, 353-356[Medline] [Order article via Infotrieve]
43. Sato, Y., Anello, M., and Henquin, J. C. (1999) Endocrinology 140, 2252-2257[Abstract/Free Full Text]
44. Meglasson, M. D., and Matschinsky, F. M. (1986) Diabetes Metab. Rev. 2, 163-214[Medline] [Order article via Infotrieve]
45. Malaisse-Lagae, F., Sener, A., Garcia-Morales, P., Valverde, I., and Malaisse, W. J. (1982) J. Biol. Chem. 257, 3754-3758[Abstract/Free Full Text]
46. Stanley, C. A., Fang, J., Kutyna, K., Hsu, B. Y. L., Ming, J. E., Glaser, B., and Poncz, M. (2000) Diabetes 49, 667-673[Abstract]
47. Detimary, P., Van Den Berghe, G., and Henquin, J. C. (1996) J. Biol. Chem. 271, 20559-20565[Abstract/Free Full Text]
48. Kelly, A., Ng, D., Ferry, R. J., Jr., Grimberg, A., Koo-Mccoy, S., Thornton, P. S., and Stanley, C. A. (2001) J. Clin. Endocrinol. Metab. 86, 3724-3728[Abstract/Free Full Text]
49. Shepherd, R. M., Gilon, P., and Henquin, J. C. (1996) Endocrinology 137, 677-685[Abstract]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
C. Broca, J. Quoyer, S. Costes, N. Linck, A. Varrault, P.-M. Deffayet, J. Bockaert, S. Dalle, and G. Bertrand
{beta}-Arrestin 1 Is Required for PAC1 Receptor-mediated Potentiation of Long-lasting ERK1/2 Activation by Glucose in Pancreatic {beta}-Cells
J. Biol. Chem., February 13, 2009; 284(7): 4332 - 4342.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. V. Jensen, J. W. Joseph, S. M. Ronnebaum, S. C. Burgess, A. D. Sherry, and C. B. Newgard
Metabolic cycling in control of glucose-stimulated insulin secretion
Am J Physiol Endocrinol Metab, December 1, 2008; 295(6): E1287 - E1297.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. Stiernet, M. Nenquin, P. Moulin, J.-C. Jonas, and J.-C. Henquin
Glucose-induced Cytosolic pH Changes in beta-Cells and Insulin Secretion Are Not Causally Related: STUDIES IN ISLETS LACKING THE NA+/H+ EXCHANGER NHE1
J. Biol. Chem., August 24, 2007; 282(34): 24538 - 24546.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Noriega-Lopez, A. R. Tovar, M. Gonzalez-Granillo, R. Hernandez-Pando, B. Escalante, P. Santillan-Doherty, and N. Torres
Pancreatic Insulin Secretion in Rats Fed a Soy Protein High Fat Diet Depends on the Interaction between the Amino Acid Pattern and Isoflavones
J. Biol. Chem., July 13, 2007; 282(28): 20657 - 20666.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
N. M. Doliba, S. L. Wehrli, M. Z. Vatamaniuk, W. Qin, C. W. Buettger, H. W. Collins, and F. M. Matschinsky
Metabolic and ionic coupling factors in amino acid-stimulated insulin release in pancreatic beta-HC9 cells
Am J Physiol Endocrinol Metab, June 1, 2007; 292(6): E1507 - E1519.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
P. Moulin, Y. Guiot, J.-C. Jonas, J. Rahier, O. Devuyst, and J.-C. Henquin
Identification and subcellular localization of the Na+/H+ exchanger and a novel related protein in the endocrine pancreas and adrenal medulla
J. Mol. Endocrinol., March 1, 2007; 38(3): 409 - 422.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
P. O. Westermark, J. H. Kotaleski, A. Bjorklund, V. Grill, and A. Lansner
A mathematical model of the mitochondrial NADH shuttles and anaplerosis in the pancreatic beta-cell
Am J Physiol Endocrinol Metab, February 1, 2007; 292(2): E373 - E393.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
J.-C. Henquin, D. Dufrane, and M. Nenquin
Nutrient Control of Insulin Secretion in Isolated Normal Human Islets
Diabetes, December 1, 2006; 55(12): 3470 - 3477.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
P. Newsholme, L. Brennan, and K. Bender
Amino Acid Metabolism, {beta}-Cell Function, and Diabetes
Diabetes, December 1, 2006; 55(Supplement_2): S39 - S47.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
M. Corless, A. Kiely, N. H McClenaghan, P. R Flatt, and P. Newsholme
Glutamine regulates expression of key transcription factor, signal transduction, metabolic gene, and protein expression in a clonal pancreatic {beta}-cell line.
J. Endocrinol., September 1, 2006; 190(3): 719 - 727.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. V. Jensen, J. W. Joseph, O. Ilkayeva, S. Burgess, D. Lu, S. M. Ronnebaum, M. Odegaard, T. C. Becker, A. D. Sherry, and C. B. Newgard
Compensatory Responses to Pyruvate Carboxylase Suppression in Islet beta-Cells: PRESERVATION OF GLUCOSE-STIMULATED INSULIN SECRETION
J. Biol. Chem., August 4, 2006; 281(31): 22342 - 22351.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
A. Wiederkehr and C. B. Wollheim
Minireview: Implication of Mitochondria in Insulin Secretion and Action
Endocrinology, June 1, 2006; 147(6): 2643 - 2649.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
N. Ishiyama, M. A. Ravier, and J.-C. Henquin
Dual mechanism of the potentiation by glucose of insulin secretion induced by arginine and tolbutamide in mouse islets
Am J Physiol Endocrinol Metab, March 1, 2006; 290(3): E540 - E549.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
S. J. Marx and W. F. Simonds
Hereditary Hormone Excess: Genes, Molecular Pathways, and Syndromes
Endocr. Rev., August 1, 2005; 26(5): 615 - 661.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. E. Rabaglia, M. P. Gray-Keller, B. L. Frey, M. R. Shortreed, L. M. Smith, and A. D. Attie
{alpha}-Ketoisocaproate-induced hypersecretion of insulin by islets from diabetes-susceptible mice
Am J Physiol Endocrinol Metab, August 1, 2005; 289(2): E218 - E224.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
P. Thams, M. R Anwar, and K. Capito
Glucose triggers protein kinase A-dependent insulin secretion in mouse pancreatic islets through activation of the K+ATP channel-dependent pathway
Eur. J. Endocrinol., April 1, 2005; 152(4): 671 - 677.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. J. MacDonald, L. A. Fahien, L. J. Brown, N. M. Hasan, J. D. Buss, and M. A. Kendrick
Perspective: emerging evidence for signaling roles of mitochondrial anaplerotic products in insulin secretion
Am J Physiol Endocrinol Metab, January 1, 2005; 288(1): E1 - E15.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Nenquin, A. Szollosi, L. Aguilar-Bryan, J. Bryan, and J.-C. Henquin
Both Triggering and Amplifying Pathways Contribute to Fuel-induced Insulin Secretion in the Absence of Sulfonylurea Receptor-1 in Pancreatic {beta}-Cells
J. Biol. Chem., July 30, 2004; 279(31): 32316 - 32324.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Li, C. Buettger, J. Kwagh, A. Matter, Y. Daikhin, I. B. Nissim, H. W. Collins, M. Yudkoff, C. A. Stanley, and F. M. Matschinsky
A Signaling Role of Glutamine in Insulin Secretion
J. Biol. Chem., April 2, 2004; 279(14): 13393 - 13401.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
T. Anno, S. Uehara, H. Katagiri, Y. Ohta, K. Ueda, H. Mizuguchi, Y. Moriyama, Y. Oka, and Y. Tanizawa
Overexpression of constitutively activated glutamate dehydrogenase induces insulin secretion through enhanced glutamate oxidation
Am J Physiol Endocrinol Metab, February 1, 2004; 286(2): E280 - E285.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
S. Yamada, M. Komatsu, Y. Sato, K. Yamauchi, T. Aizawa, and I. Kojima
Nutrient Modulation of Palmitoylated 24-Kilodalton Protein in Rat Pancreatic Islets
Endocrinology, December 1, 2003; 144(12): 5232 - 5241.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
Y.-J. Liu, H. Cheng, H. Drought, M. J. MacDonald, G. W. G. Sharp, and S. G. Straub
Activation of the KATP channel-independent signaling pathway by the nonhydrolyzable analog of leucine, BCH
Am J Physiol Endocrinol Metab, August 1, 2003; 285(2): E380 - E389.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Li, H. Najafi, Y. Daikhin, I. B. Nissim, H. W. Collins, M. Yudkoff, F. M. Matschinsky, and C. A. Stanley
Regulation of Leucine-stimulated Insulin Secretion and Glutamine Metabolism in Isolated Rat Islets
J. Biol. Chem., January 24, 2003; 278(5): 2853 - 2858.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/36/32883    most recent
M205326200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bertrand, G.
Right arrow Articles by Henquin, J.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bertrand, G.
Right arrow Articles by Henquin, J.-C.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement